Ligand Pharmaceuticals Incorporated (LGND) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ligand Pharmaceuticals Incorporated (LGND) has a cash flow conversion efficiency ratio of 0.025x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($24.02 Million) by net assets ($967.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LGND market cap overview for the company's overall valuation and market capitalisation.
Ligand Pharmaceuticals Incorporated - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how Ligand Pharmaceuticals Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ligand Pharmaceuticals Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ligand Pharmaceuticals Incorporated ranked by their cash flow conversion efficiency. Explore Ligand Pharmaceuticals Incorporated earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DigitalOcean Holdings Inc
NYSE:DOCN
|
-1.997x |
|
Matador Resources Company
NYSE:MTDR
|
0.150x |
|
Nice Ltd ADR
NASDAQ:NICE
|
0.049x |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
-0.148x |
|
Astor Enerji AS
IS:ASTOR
|
0.068x |
|
CICT Mobile Communication Technology Co. Ltd. A
SHG:688387
|
N/A |
|
Hunan Gold Corp Ltd
SHE:002155
|
0.031x |
|
Spring Airlines Co Ltd
SHG:601021
|
0.142x |
Annual Cash Flow Conversion Efficiency for Ligand Pharmaceuticals Incorporated (1994–2025)
The table below shows the annual cash flow conversion efficiency of Ligand Pharmaceuticals Incorporated from 1994 to 2025. View Ligand Pharmaceuticals Incorporated stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.02 Billion | $49.36 Million | 0.049x | -58.48% |
| 2024-12-31 | $830.44 Million | $97.05 Million | 0.117x | +65.22% |
| 2023-12-31 | $700.91 Million | $49.58 Million | 0.071x | -69.34% |
| 2022-12-31 | $597.49 Million | $137.85 Million | 0.231x | +140.43% |
| 2021-12-31 | $821.16 Million | $78.80 Million | 0.096x | +24.73% |
| 2020-12-31 | $709.52 Million | $54.59 Million | 0.077x | +301.21% |
| 2019-12-31 | $767.23 Million | $-29.34 Million | -0.038x | -111.05% |
| 2018-12-31 | $560.91 Million | $194.06 Million | 0.346x | +54.80% |
| 2017-12-31 | $418.65 Million | $93.57 Million | 0.224x | +31.56% |
| 2016-12-31 | $370.85 Million | $63.00 Million | 0.170x | +23.93% |
| 2015-12-31 | $304.39 Million | $41.73 Million | 0.137x | -83.73% |
| 2014-12-31 | $24.41 Million | $20.57 Million | 0.843x | +102.05% |
| 2013-12-31 | $49.61 Million | $20.69 Million | 0.417x | +6760.24% |
| 2012-12-31 | $26.48 Million | $161.00K | 0.006x | +104.48% |
| 2011-12-31 | $8.65 Million | $-1.17 Million | -0.136x | -103.50% |
| 2010-12-31 | $-6.99 Million | $-27.07 Million | 3.872x | +142.89% |
| 2009-12-31 | $3.74 Million | $-33.80 Million | -9.028x | -553.70% |
| 2008-12-31 | $-10.37 Million | $-20.62 Million | 1.990x | +159.28% |
| 2007-12-31 | $29.11 Million | $-97.73 Million | -3.357x | +33.72% |
| 2006-12-31 | $27.35 Million | $-138.52 Million | -5.064x | -6585.05% |
| 2005-12-31 | $-110.42 Million | $8.37 Million | -0.076x | +0.84% |
| 2004-12-31 | $-75.32 Million | $5.75 Million | -0.076x | -2072.05% |
| 2003-12-31 | $70.73 Million | $274.00K | 0.004x | +101.14% |
| 2002-12-31 | $74.02 Million | $-25.11 Million | -0.339x | -198.64% |
| 2001-12-31 | $-57.88 Million | $-19.91 Million | 0.344x | -59.96% |
| 2000-12-31 | $-55.12 Million | $-47.35 Million | 0.859x | -63.65% |
| 1999-12-31 | $-25.60 Million | $-60.50 Million | 2.363x | -59.55% |
| 1998-12-31 | $-11.40 Million | $-66.60 Million | 5.842x | +1595.40% |
| 1997-12-31 | $34.30 Million | $-13.40 Million | -0.391x | +59.53% |
| 1996-12-31 | $34.50 Million | $-33.30 Million | -0.965x | +28.44% |
| 1995-12-31 | $28.10 Million | $-37.90 Million | -1.349x | -148.06% |
| 1994-12-31 | $26.30 Million | $-14.30 Million | -0.544x | -- |
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help figh… Read more